Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

New Unexpected Data on Non-Culprit Vessels in MI

Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant. 

Nueva y discrepante información sobre los vasos no culpables en el infarto

Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning.  This pre-conditioning, according to this perspective, would reduce reperfusion injury and translate into reduced infarct size. 

Ischemic preconditioning model may be used in patients with functionally significant lesions in other vessels presenting MI. 

The aim of this stud was to look into the link between functional multivessel disease and reduced infarct size in a large contemporary cohort of patients

A cardiac MR was done in 610 patients undergoing primary PCI on day 1 and after 3 months

Patients were stratified in 3 groups according to FFR measurements in non-culprit lesions: angiographic single vessel disease, FFR nonsignificant single vessel disease, or FFR-significant functional multivessel disease. 


Read also: The Key to Treating Stroke: Knowing When to Stop.


431 patients presented angiographic single vessel disease (71%), 35 had functional single vessel disease (6%) and 144 had functional multivessel disease (23%).

There were no significant differences in infarct size or myocardial salvage index between groups. Functional multivessel disease was not associated with larger myocardial salvage (p=0.56) or smaller infarct size (p=0.55).

These outcomes raise questions about remote ischemic pre-conditioning. 

Conclusion

Functional multivessel disease in patients undergoing primary PCI is not associated to reduced infarct size or improve myocardial salvage index.  This is important information for future cardioprotective treatment of MI patients. 

Título original: Ischemia From Nonculprit Stenosis Is Not Associated With Reduced Culprit Infarct Size in Patients with ST-Segment–Elevation Myocardial Infarction.

Referencia: Kathrine Ekström et al. Circ Cardiovasc Imaging. 2021 May 5. Online ahead of print. doi: 10.1161/CIRCIMAGING.120.012290. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...